Igf-1 lr3 is a polypeptide amino acid that is sometimes referred to as Long r3 igf-1. Because of its molecule build and structural properties, it is sometime confused with a similar peptide known as Long r2 ifg-1.
Functionality of Igf-1 lr3
According to scientific research conducted on animal test subjects, Igf-1 lr3 works in conjunction with secretions conducted by the liver. It has been shown that these secretions function as a disposal agent for glucose throughout the animal test subject’s body. The secretions are considered to be highly anabolic, meaning that their processes tend toward building organs and tissues through the chemical reactions of complex molecules. Thus, the peptide acts to manage insulin dispersal, which in turn encourages primary muscular growth. The secretion is particularly spiked during an animal test subject’s developmental stages into full maturity. The downside to these secretions is that they have a very rapid half life, lasting only around 20 minutes.
Igf-1 lr3 functions to extend the half-life of these liver secretions. It does so by prohibiting the deactivation of binding proteins in the bloodstream of animal test subjects. This process extends the half-life of the secretion to approximately 20 hours; a time frame in which the secretion maintains proper functionality without the consequences of degradation. The extended half-life enables the following to occur in animal test subjects:
- Increased transport of amino acids to cells
- Increased transport of glucose
- Increased protein synthesis
- Decreased protein degradation
- Increased synthesis of RNA
Scientific study on animal test subjects has also led to the conclusion that the peptide can also elevate protein synthesis and nitrogen retention.
Benefits of Igf-1 lr3
Scientific research conducted on animal test subjects in relation to Igf-1 lr3 have concluded that the peptide is linked to several theoretical benefits. These theoretical benefits include:
- Increased muscle retention – Because of Igf-1 lr3’s extended half-life, the peptide enables a longer period of the secretions that regulate muscular repair and growth to occur. As a result, scientific study on animal test subjects have determined that this extended half-life causes an increased ability for an animal test subject to maintain and preserve muscular shape and tone.
- Increased endurance – Scientific research conducted on animal test subjects have determined that Igf-1 lr3’s properties in relation to promoting protein synthesis and prohibiting protein degradation allows for increased intervals of muscular performance before the inhibition that comes from fatigue occurs.
- More efficient injury recovery – Because of the peptide’s capability to extend the half-life of secretions related to muscular repair, scientific study on animal test subjects have determined that this process enables an increased instance of repair for muscles, tissues, and skeletal structures. Thus, the peptide has been determined to play a key role in enabling animal test subjects to heal from injury quicker.
Side Effects of Igf-1 lr3
While there have been several theoretical benefits relating to the use of Igf-1 lr3 that have thus far been derived from scientific research conducted on animal test subjects, studies have also derived a few negative side effects that have been theoretically linked to the peptide.
The most prominent negative side effect that has been linked to the peptide’s use is related to hypoglycemia. This condition involves an unusually lowered amount of glucose that is found in the blood (aka “low blood sugar”). According to scientific study based on animal test subjects, it is a condition that is thought to be the product of Igf-1 lr3’s ability to promote the transport of glucose in a more efficient manner. Studies on animal test subjects also show that this negative side effect can be counteracted with an increased intake of glucose for the animal test subject to distribute.
Other potential negative side effects may include:
- Drop in blood pressure
- Swelling of the extremities
- Irregularities relating to the cardiovascular system, including cardiac arrest
For Scientific Use Only
Despite the fact that scientific study has been conducted on animal test subjects to gauge Igf-1 lr3’s range of operational mechanics and functionality including its theoretical benefits and possible negative side effects, it should be noted that any and all findings that have been linked to the peptide are still based in current laboratory research. Because Igf-1 lr3 is currently in this research phase, any usage or study pertaining to the overall mechanics, operational effects, benefits, and side effects of the peptide should solely be contained to the restrictions of a strictly controlled environment such as a laboratory or medical research facility.